Study setting

From May 2020 to March 2021, three South Korean tertiary academic hospitals participated in this prospective multi-center, randomized study (ClinicalTrials.gov ID NCT04297293), which was approved by the institutional review board of the following centers: Seoul National University Bundang Hospital (Gyeonggi, South Korea, IRB No. B-2002/594-003), Ajou University Medical Center (Gyeonggi, South Korea, IRB No. AJIRB-MED-INT-20-039), and Chung-Ang University Hospital (Seoul, South Korea, IRB No. 2060-003-420). Written, informed consents were obtained from all participants prior to their enrollment.

Participants and trial design

Female patients (age range 18–49 years) with American Society of Anesthesiologists physical status 1 or 2 and scheduled for day surgery under general anesthesia were included in this randomized clinical trial. Patients who were pregnant or breastfeeding, taking other serotonin receptor antagonists, or had Lapp lactase deficiency, galactose intolerance, or glucose-galactose malabsorption prior to the study were excluded.

Randomization

This was a parallel, block-randomized trial (block sizes of 6 and 8) with an allocation ratio of 1:1. The randomization table was created using a web-based randomization system (http://www.randomization.com). An anesthesiologist not involved in the study was in charge of randomization and prepared opaque, sealed envelopes containing a slip of paper with a computer-generated description of whether the patient would receive ramosetron ODT (ramosetron group) or not (control group).

Blinding

The investigating anesthesiologist who performed the outcome assessment was not blinded to the groups, since he was required to assess drug compliance as per the trial protocol.

Anesthesia

None of the patients received any preoperative medication. Standard monitoring (blood pressure, electrocardiogram, and pulse oximetry) was performed. In addition, to ensure maintenance of adequate anesthetic depth, the bispectral index (BIS™, Covidien Inc., USA) was recorded. Anesthesia was induced with intravenous pentothal (5 mg/kg), sevoflurane (Sevofran®, HANA PHARM Co., Ltd., South Korea) or desflurane (Suprane®, Baxter Health Corporation, USA), remifentanil (Ultiva®, GlaxoSmithKlein, UK) with a target-controlled infusion device (Orchestra®, Fresenius Vial, France), and rocuronium (0.6 mg/kg). For ventilation support, a laryngeal mask airway (i-gel®, Intersurgical Ltd., UK) or endotracheal tube was placed. Furthermore, mechanical ventilation was controlled to maintain end-tidal carbon dioxide at 33–38 mmHg. A continuous infusion of remifentanil and a volatile agent (sevoflurane or desflurane) was used to maintain anesthesia. Ringer’s lactate solution was infused at a rate of 5 mL/kg/h.

For postoperative pain control, either fentanyl 50 μg (when the verbal numerical rating scale (VNRS) > 5; VNRS 0 = “no pain” and VNRS 100 = “worst pain imaginable”) or ketorolac 30 mg (when the VNRS ≤ 5) was administered intravenously.

PONV control (in-hospital)

After surgery, patients who suffered from nausea or vomiting were administered ramosetron 0.3 mg intravenously at the first episode. For subsequent episodes of nausea or vomiting, a single dose of 10 mg metoclopramide was given intravenously. Nausea was defined as a subjective feeling of being sick, and vomiting was defined as an expulsion of gastric contents or retching. This protocol was applied in both the patient groups.

PDNV control (after discharge)

Ramosetron group

In the ramosetron group, ramosetron ODT 0.1 mg was administered on the morning of postoperative days 1 and day 2 as a prophylactic antiemetic after discharge. If there was nausea and/or vomiting before or after the administration of ramosetron ODT, metoclopramide 10 mg was administered as a rescue antiemetic, at a maximum dose of 30 mg per day.

Control group

In the control group, patients were administered only metoclopramide 10 mg for the treatment of nausea and/or vomiting at a maximum dose of 30 mg per day.

Outcome measurements

The primary outcome was the incidence of nausea during the 24 h after discharge. The secondary outcomes included the incidence of nausea and vomiting (30 min and 3 h postoperatively, and 48 h after discharge), severity of nausea, and the rate of rescue antiemetic (metoclopramide) administration. Additionally, we investigated the pain scores and the dosage of analgesic used. The severity of nausea (0 = “no nausea” and 100 = “worst nausea imaginable”) and pain (0 = “no pain” and 100 = “worst pain imaginable”) was measured using the VNRS. The investigators interviewed the patients 24 and 48 h post-anesthesia by telephone.

Sample size

By assuming that the incidence of post-discharge nausea was 30% (the overall incidence in patients who have two risk factors for PDNV) in the control group and 10% in the ramosetron group (about 70% reduction in the incidence of nausea from the control group), and that this difference was clinically significant, we calculated that 138 patients were needed to be recruited to achieve 80% power to detect this difference at a two-sided alpha level of 0.05, considering a 10% drop out rate.

Statistical analysis

After normality check of variables using the Shapiro-Wilk test, continuous variables were compared with Student’s t test or Mann-Whitney U test and expressed as the mean (standard deviation (SD)) or median (interquartile range (IQR)), as appropriate. For categorical data, a chi-square test or Fisher’s exact test was used, and the results were described as a number (proportion). All analyses were carried out using IBM® SPSS® Statistics version 25.0 (IBM Corporation, NY, USA). P < 0.05 was considered as statistically significant.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Disclaimer:

This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

Click here for Source link (https://www.biomedcentral.com/)